

Paolo Bossi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7245433/paolo-bossi-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

268
papers

6,164
citations

41
h-index

70
g-index

297
ext. papers

7,887
ext. citations

4.3
avg, IF

5.57
L-index

#	Paper	IF	Citations
268	The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts.. <i>Cancers</i> , 2022 , 14,	6.6	3
267	A nationwide survey among emergency physicians and oncologists to improve the management of immune checkpoint inhibitors toxicity.. <i>Supportive Care in Cancer</i> , 2022 , 1	3.9	
266	Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group.. <i>Frontiers in Oncology</i> , 2022 , 12, 730785	5.3	0
265	Biological properties of hypoxia-related gene expression models/signatures on clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity trials.. <i>Oral Oncology</i> , 2022 , 126, 105756	4.4	
264	Baseline prognostic factors affecting survival in recurrent and/or metastatic salivary gland adenoid cystic carcinoma.. <i>Oral Oncology</i> , 2022 , 126, 105764	4.4	0
263	Different inflammatory blood markers correlate with specific outcomes in incident HPV-negative head and neck squamous cell carcinoma: a retrospective cohort study.. <i>BMC Cancer</i> , 2022 , 22, 243	4.8	1
262	Clinical and Histological Prognostic Factors of Recurrence and Malignant Transformation in a Large Series of Oral Potentially Malignant Disorders.. <i>Frontiers in Oncology</i> , 2022 , 12, 886404	5.3	
261	The Role of Systemic Therapy and Targeted Approaches for the Treatment of Sinonasal Malignancies 2022 , 195-204		
260	New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Vaccines</i> , 2022 , 10, 885	5.3	0
259	Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma.. <i>European Journal of Cancer</i> , 2021 ,	7.5	5
258	Treatment of Cutaneous Squamous Cell Carcinoma with Immune Checkpoint Inhibitors in Special Populations. <i>Dermatology Practical and Conceptual</i> , 2021 , 11, e20211705	1.5	0
257	Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort. <i>European Journal of Cancer</i> , 2021 , 159, 194-204	7.5	6
256	Immunotherapy for Cutaneous Squamous Cell Carcinoma: Results and Perspectives.. <i>Frontiers in Oncology</i> , 2021 , 11, 727027	5.3	1
255	Accurate Triage of Oncological Patients for Safely Continuing Cancer Therapy During the SARS-CoV-2 Pandemic. <i>Frontiers in Oncology</i> , 2021 , 11, 707346	5.3	0
254	Oral potentially malignant disorders: new insights for future treatment. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2021 , 29, 138-142	2	2
253	The role of benzydamine in prevention and treatment of chemoradiotherapy-induced mucositis. <i>Supportive Care in Cancer</i> , 2021 , 29, 5701-5709	3.9	3
252	The appropriate use of circulating EBV-DNA in nasopharyngeal carcinoma: Comprehensive clinical practice guidelines evaluation. <i>Oral Oncology</i> , 2021 , 114, 105128	4.4	2

251	Sinonasal cancers treatments: state of the art. <i>Current Opinion in Oncology</i> , 2021 , 33, 196-205	4.2	5
250	Immunonutrition in head and neck cancer patients undergoing chemoradiotherapy: an alternative approach for overcoming potential bias. <i>American Journal of Clinical Nutrition</i> , 2021 , 113, 1053-1054	7	1
249	M. D. Anderson symptom inventory head neck (MDASI-HN) questionnaire: Italian language psychometric validation in head and neck cancer patients treated with radiotherapy and systemic therapy - A study of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). <i>Oral Oncology</i> , 2021 , 115, 105189	4.4	3
248	Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carcinoma. <i>Oral Oncology</i> , 2021 , 115, 105213	4.4	8
247	Immunotherapy for the prevention of high-risk oral disorders malignant transformation: the IMPEDE trial. <i>BMC Cancer</i> , 2021 , 21, 561	4.8	0
246	Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies. <i>Cancers</i> , 2021 , 13,	6.6	6
245	Gene Expression Profiling of Olfactory Neuroblastoma Helps Identify Prognostic Pathways and Define Potentially Therapeutic Targets. <i>Cancers</i> , 2021 , 13,	6.6	5
244	Prognostic role of pre-treatment magnetic resonance imaging (MRI)-based radiomic analysis in effectively cured head and neck squamous cell carcinoma (HNSCC) patients. <i>Acta Oncologica</i> , 2021 , 60, 1192-1200	3.2	1
243	Brain metastasis in head and neck squamous cell carcinoma after immune check point inhibitors treatment. <i>Oral Oncology</i> , 2021 , 116, 105138	4.4	0
242	Malignant salivary gland tumours in families with breast cancer susceptibility. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021 , 479, 221-226	5.1	
241	A European survey on the practice of nutritional interventions in head-neck cancer patients undergoing curative treatment with radio(chemo)therapy. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021 , 1	3.5	0
240	Survival and toxicity of weekly cisplatin chemoradiotherapy versus three-weekly cisplatin chemoradiotherapy for head and neck cancer: A systematic review and meta-analysis endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). <i>Critical Reviews in Oncology/Neuro-Oncology</i> , 2021 , 119, 100017	7	2
239	Regional disease in head and neck cutaneous squamous cell carcinoma: the role of primary tumor characteristics and number of nodal metastases. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021 , 1	3.5	1
238	What to Do and What Not to Do in the Management of Cancer Pain: A Physician Survey and Expert Recommendations. <i>Cancer Management and Research</i> , 2021 , 13, 5203-5210	3.6	
237	Sinonasal Squamous Cell Carcinoma, a Narrative Reappraisal of the Current Evidence. <i>Cancers</i> , 2021 , 13,	6.6	3
236	The Spectrum of Malnutrition/Cachexia/Sarcopenia in Oncology According to Different Cancer Types and Settings: A Narrative Review. <i>Nutrients</i> , 2021 , 13,	6.7	21
235	Prognostic value of H-index in patients surgically treated for squamous cell carcinoma of the larynx. <i>Laryngoscope Investigative Otolaryngology</i> , 2021 , 6, 729-737	2.8	0
234	Overview of Oral Potentially Malignant Disorders: From Risk Factors to Specific Therapies. <i>Cancers</i> , 2021 , 13,	6.6	2

233	MASCC/ISOO clinical practice guidelines for the management of mucositis: sub-analysis of current interventions for the management of oral mucositis in pediatric cancer patients. <i>Supportive Care in Cancer</i> , 2021 , 29, 3539-3562	3.9	10
232	Defining the needs of patients with recurrent and/or metastatic head and neck cancer: An expert opinion. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 157, 103200	7	3
231	Psychometric properties of the Italian version of the Speech Handicap Index. <i>Disability and Rehabilitation</i> , 2021 , 43, 1307-1312	2.4	1
230	Optimal Supportive Measures during Primary Treatment 2021 , 221-230		
229	The efficacy of immunonutrition in improving tolerance to chemoradiotherapy in patients with head and neck cancer, receiving nutritional counseling: study protocol of a randomized, open-label, parallel group, bicentric pilot study. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211025872	5.4	0
228	Peripherally or centrally inserted central catheters: what is the best vascular access device for cancer patients?. <i>Supportive Care in Cancer</i> , 2021 , 29, 2803-2806	3.9	1
227	Prognostic Significance of CD4+ and CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis. <i>Cancers</i> , 2021 , 13,	6.6	15
226	Sinonasal cancer encroaching the orbit: Ablation or preservation?. <i>Oral Oncology</i> , 2021 , 114, 105185	4.4	9
225	Patient selection for immunotherapy in head and neck cancer. <i>Lancet Oncology, The</i> , 2021 , 22, e290	21.7	1
224	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	1
223	Vitamin D Supplementation and Cancer Mortality: Narrative Review of Observational Studies and Clinical Trials. <i>Nutrients</i> , 2021 , 13,	6.7	3
222	Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial. <i>Journal of Clinical Oncology</i> , 2021 , JCO2100468	2.2	6
221	Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. <i>European Journal of Cancer</i> , 2021 , 157, 250-258	7.5	6
220	The impact of the COVID-19 outbreak on supportive care for oral mucositis: current concepts and practice. <i>Supportive Care in Cancer</i> , 2021 , 29, 2255-2258	3.9	2
219	Genome-wide study of salivary miRNAs identifies miR-423-5p as promising diagnostic and prognostic biomarker in oral squamous cell carcinoma. <i>Theranostics</i> , 2021 , 11, 2987-2999	12.1	17
218	New and Promising Targeted Therapies in First and Second-Line Settings 2021 , 277-296		
217	Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study. <i>Future Oncology</i> , 2020 , 16, 1091-1100	3.6	1
216	Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives. <i>Supportive Care in Cancer</i> , 2020 , 28, 4589-4612	3.9	47

215	Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders. <i>Oncologist</i> , 2020 , 25, e946-e954	5.7	2
214	Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action. <i>Supportive Care in Cancer</i> , 2020 , 28, 5059-5073	3.9	16
213	Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands. <i>European Journal of Cancer</i> , 2020 , 136, 35-42	7.5	8
212	Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life. <i>Cancer</i> , 2020 , 126, 1888-1894	6.4	21
211	A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 187-204	4.1	1
210	Relevance of apparent diffusion coefficient features for a radiomics-based prediction of response to induction chemotherapy in sinonasal cancer. <i>NMR in Biomedicine</i> , 2020 , e4265	4.4	3
209	Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines. <i>Supportive Care in Cancer</i> , 2020 , 28, 2485-2498	3.9	20
208	Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients and clinical practice guidelines. <i>Supportive Care in Cancer</i> , 2020 , 28, 2473-2484	3.9	29
207	Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and clinical practice guidelines - part 2: honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents. <i>Supportive Care in Cancer</i> , 2020 , 28, 2457-2472	3.9	26
206	Tumor Biomarkers for the Prediction of Distant Metastasis in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	9
205	Precision medicine in rare tumors and the need for multicenter trials and international collaboratives: Sinonasal cancer as paradigm. <i>Oral Oncology</i> , 2020 , 109, 104737	4.4	2
204	Treatment Options for Recurrent Anterior Skull Base Tumors. <i>Advances in Oto-Rhino-Laryngology</i> , 2020 , 84, 231-245	1.7	2
203	Future Perspectives in the Management of Tumors of the Anterior Skull Base. <i>Advances in Oto-Rhino-Laryngology</i> , 2020 , 84, 246-250	1.7	0
202	Prognostic role of pre-treatment magnetic resonance imaging (MRI) radiomic analysis in patients with squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 6553-6553	3.2	3
201	Randomized Phase 2 Trial of a Novel Clonidine Mucoadhesive Buccal Tablet for the Amelioration of Oral Mucositis in Patients Treated With Concomitant Chemoradiation Therapy for Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 106, 320-328	4	12
200	Is pain part of a systemic syndrome in head and neck cancer?. <i>Supportive Care in Cancer</i> , 2020 , 28, 451-459	3.9	6
199	Management of sinonasal adenocarcinomas with anterior skull base extension. <i>Journal of Neuro-Oncology</i> , 2020 , 150, 405-417	4.8	7
198	Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines. <i>Supportive Care in Cancer</i> , 2020 , 28, 2449-2456	3.9	29

197	Role of IMRT/VMAT-Based Dose and Volume Parameters in Predicting 5-Year Local Control and Survival in Nasopharyngeal Cancer Patients. <i>Frontiers in Oncology</i> , 2020 , 10, 518110	5.3	4
196	Baseline MRI-Radiomics Can Predict Overall Survival in Non-Endemic EBV-Related Nasopharyngeal Carcinoma Patients. <i>Cancers</i> , 2020 , 12,	6.6	15
195	Value and Quality of Care in Head and Neck Oncology. <i>Current Oncology Reports</i> , 2020 , 22, 92	6.3	8
194	Patients with locally advanced and metastatic cutaneous squamous cell carcinoma treated with immunotherapy in the era of COVID-19: stop or go? Data from five Italian referral cancer centers. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920977002	5.4	3
193	Gene Expression Clustering and Selected Head and Neck Cancer Gene Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions. <i>Cells</i> , 2020 , 9,	7.9	6
192	A randomized, double-blind, placebo controlled, phase II study to evaluate the efficacy of ginseng in reducing fatigue in patients treated for head and neck cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 2479-2487	4.9	3
191	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. <i>Cancer</i> , 2020 , 126, 4423-4431	6.4	82
190	The Evolving Role of Systemic Therapy in the Primary Treatment of Sinonasal Cancer. <i>Advances in Oto-Rhino-Laryngology</i> , 2020 , 84, 78-86	1.7	1
189	Pretreatment DWI with Histogram Analysis of the ADC in Predicting the Outcome of Advanced Oropharyngeal Cancer with Known Human Papillomavirus Status Treated with Chemoradiation. <i>American Journal of Neuroradiology</i> , 2020 , 41, 1473-1479	4.4	8
188	The 8th TNM classification for oral squamous cell carcinoma: What is gained, what is lost, and what is missing. <i>Oral Oncology</i> , 2020 , 111, 104937	4.4	9
187	A monocentric, open-label randomized standard-of-care controlled study of XONRID [®] , a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients. <i>Radiation Oncology</i> , 2020 , 15, 193	4.2	0
186	The Spread of SARS-CoV-2 Infection Among the Medical Oncology Staff of ASST Spedali Civili of Brescia: Efficacy of Preventive Measures. <i>Frontiers in Oncology</i> , 2020 , 10, 1574	5.3	3
185	Locally advanced epithelial sinonasal tumors: The impact of multimodal approach. <i>Laryngoscope</i> , 2020 , 130, 857-865	3.6	10
184	Prognostic role of primary tumor, nodal neck, and retropharyngeal GTVs for unresectable sinonasal cancers treated with IMRT and chemotherapy. <i>Tumori</i> , 2020 , 106, 39-46	1.7	3
183	Malignant tumors of the maxillary sinus: Prognostic impact of neurovascular invasion in a series of 138 patients. <i>Oral Oncology</i> , 2020 , 106, 104672	4.4	9
182	A pilot study of a smartphone-based monitoring intervention on head and neck cancer patients undergoing concurrent chemo-radiotherapy. <i>International Journal of Medical Informatics</i> , 2019 , 129, 404-412	5.3	15
181	Difficulties in conducting pure academic research, obstacles in data collection and quality of informations: The example of the INTERCEPTOR study. <i>Oral Oncology</i> , 2019 , 97, 99-104	4.4	1
180	Postoperative radiotherapy (PORT) for early oral cavity cancer (pT1-2,N0-1): A review. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 143, 67-75	7	13

179	Quality Assessment in Supportive Care in Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2019 , 9, 926	5.3	6
178	Rationale and budget impact of bimonthly use of Cetuximab in patients with recurrent and/or metastatic head and neck cancer. <i>Head and Neck</i> , 2019 , 41, 908-914	4.2	1
177	Prognostic Nomograms in Oral Squamous Cell Carcinoma: The Negative Impact of Low Neutrophil to Lymphocyte Ratio. <i>Frontiers in Oncology</i> , 2019 , 9, 339	5.3	24
176	May we rely on induction chemotherapy again as a biological selection of radiosensitive head and neck cancer?. <i>Oral Oncology</i> , 2019 , 94, 121-122	4.4	1
175	PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents. <i>Oncology</i> , 2019 , 97, 112-118	3.6	1
174	Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting. <i>European Journal of Cancer</i> , 2019 , 115, 4-12	7.5	13
173	Identification of potentially druggable molecular alterations in skin adnexal malignancies. <i>Journal of Dermatology</i> , 2019 , 46, 507-514	1.6	4
172	Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 435-443	5.9	5
171	Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 137, 84-91	7	24
170	The point of pain in head and neck cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 138, 51-59	7	13
169	A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypes. <i>Oral Oncology</i> , 2019 , 90, 94-101	4.4	7
168	The role of age in treatment-related adverse events in patients with head and neck cancer: A systematic review. <i>Head and Neck</i> , 2019 , 41, 2410-2429	4.2	12
167	Prevalence of Fatigue in Head and Neck Cancer Survivors. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2019 , 128, 413-419	2.1	10
166	Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer. <i>Dysphagia</i> , 2019 , 34, 52-62	3.7	5
165	Could the extreme conformality achieved with proton therapy in paranasal sinuses cancers accidentally results in a high rate of leptomeningeal progression?. <i>Head and Neck</i> , 2019 , 41, 3733-3735	4.2	0
164	Development of the MASCC/ISOO clinical practice guidelines for mucositis: an overview of the methods. <i>Supportive Care in Cancer</i> , 2019 , 27, 3933-3948	3.9	25
163	Surveillance of Patients with Head and Neck Cancer with an Intensive Clinical and Radiologic Follow-up. <i>Otolaryngology - Head and Neck Surgery</i> , 2019 , 161, 635-642	5.5	12
162	Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines. <i>Supportive Care in Cancer</i> , 2019 , 27, 3949-3967	3.9	63

161	Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines. <i>Supportive Care in Cancer</i> , 2019 , 27, 3969-3983	3.9	119
160	The pathogenesis of mucositis: updated perspectives and emerging targets. <i>Supportive Care in Cancer</i> , 2019 , 27, 4023-4033	3.9	57
159	Systematic review of natural and miscellaneous agents for the management of oral mucositis in cancer patients and clinical practice guidelines-part 1: vitamins, minerals, and nutritional supplements. <i>Supportive Care in Cancer</i> , 2019 , 27, 3997-4010	3.9	35
158	Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients and clinical practice guidelines. <i>Supportive Care in Cancer</i> , 2019 , 27, 3985-3995	3.9	41
157	Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. <i>Supportive Care in Cancer</i> , 2019 , 27, 4011-4022	3.9	26
156	Mining of Self-Organizing Map Gene-Expression Portraits Reveals Prognostic Stratification of HPV-Positive Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2019 , 11,	6.6	12
155	Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract. <i>Head and Neck</i> , 2019 , 41, 3670-3676	4.2	12
154	Cost-effectiveness of Molecular Profile Patient Selection for First-line Treatment of Recurrent/Metastatic Head and Neck Cancer. <i>Clinical Therapeutics</i> , 2019 , 41, 2517-2528.e28	3.5	1
153	Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma. <i>European Journal of Cancer</i> , 2019 , 123, 138-145	7.5	9
152	Hyperprogressive disease (HPD) in head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6029-6029	2.2	1
151	Clinical prognostic factors in patients with recurrent or metastatic carcinoma of the head and neck treated with immune checkpoints therapies.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e17530-e17530	2.2	2
150	Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment. <i>Drugs in Context</i> , 2019 , 8, 212611	5.2	3
149	AUCtox: A new method to evaluate the safety of anticancer drugs in metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 290-290	2.2	
148	Retrospective analysis of baseline clinical factors associated to CDDP-nephrotoxicity in locally advanced head and neck cancer (LAHNC) patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e17537-e17537 ²		
147	Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 1909-1915	6.1	13
146	Systematic Review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy. <i>Future Oncology</i> , 2019 , 15, 2543-2553	3.6	6
145	Systemic treatment in elderly head and neck cancer patients: recommendations for clinical practice. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2019 , 27, 142-150	2	16
144	Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2019 , 41, 1895-1902	4.2	5

143	Role of pretreatment 18F-FDG PET/CT parameters in predicting outcome of non-endemic EBV DNA-related nasopharyngeal cancer (NPC) patients treated with IMRT and chemotherapy. <i>Radiologia Medica</i> , 2019 , 124, 414-421	6.5	13
142	Global cancer control: responding to the growing burden, rising costs and inequalities in access. <i>ESMO Open</i> , 2018 , 3, e000285	6	98
141	Lenvatinib-induced renal failure: two first-time case reports and review of literature. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 379-385	5.5	21
140	Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN). <i>Annals of Oncology</i> , 2018 , 29, 985-991	10.3	21
139	Comment on P Human papillomavirus association is the most important predictor for surgically treated patients with oropharyngeal cancer? <i>British Journal of Cancer</i> , 2018 , 118, e5	8.7	1
138	Failure of Further Validation for Survival Nomograms in Oropharyngeal Cancer: Issues and Challenges. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 100, 1217-1221	4	9
137	Retreatment with Vismodegib after Progression in Advanced Basal Cell Carcinoma: First-Time Report of a Single-Institution Experience. <i>Targeted Oncology</i> , 2018 , 13, 253-256	5	8
136	Prognostic role of PIK3CA and TP53 in human papillomavirus-negative oropharyngeal cancers. <i>Tumori</i> , 2018 , 104, 213-220	1.7	2
135	Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs. <i>Cancer Treatment Reviews</i> , 2018 , 65, 78-86	14.4	24
134	Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2018 , 29, iv126-iv142	12.3	41
133	Addressing the quality of life needs of older patients with cancer: a SIOG consensus paper and practical guide. <i>Annals of Oncology</i> , 2018 , 29, 1718-1726	10.3	56
132	The use of intensive radiological assessments in routine surveillance after treatment for head and neck cancer: An economic evaluation. <i>European Journal of Cancer</i> , 2018 , 93, 89-98	7.5	7
131	Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial. <i>Oral Oncology</i> , 2018 , 82, 144-151	4.4	11
130	Fatigue, a major still underestimated issue. <i>Current Opinion in Oncology</i> , 2018 , 30, 219-225	4.2	15
129	Phase II study on lenvatinib (LEN) in recurrent and/or metastatic (R/M) adenoid cystic carcinomas (ACC) of the salivary glands (SG) of the upper aereodigestive tract (NCT02860936).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6086-6086	2.2	6
128	The use of fentanyl in pain management in head and neck cancer patients: a narrative review. <i>British Journal of Pain</i> , 2018 , 12, 155-162	2.1	7
127	Impact of treatment expertise on the outcome of patients with head and neck cancer treated within 6 randomized trials. <i>Head and Neck</i> , 2018 , 40, 2648-2656	4.2	6
126	In Reply to Fakhry et'al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, 670-671	4	1

125	Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients. <i>Oral Oncology</i> , 2018 , 86, 266-272	4.4	17
124	Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. <i>European Journal of Cancer</i> , 2018 , 97, 7-15	7.5	23
123	Managing older patients with head and neck cancer: The non-surgical curative approach. <i>Journal of Geriatric Oncology</i> , 2018 , 9, 411-417	3.6	6
122	Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm?. <i>Oral Oncology</i> , 2017 , 66, 58-63	4.4	70
121	Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy. <i>Oral Oncology</i> , 2017 , 69, 33-37	4.4	14
120	Toward Personalized Cancer Care for Elderly Head and Neck Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 98, 965-966	4	4
119	Eliciting Preferences for Clinical Follow-Up in Patients with Head and Neck Cancer Using Best-Worst Scaling. <i>Value in Health</i> , 2017 , 20, 799-808	3.3	7
118	Preemptive treatment with Xonrid [®] , a medical device to reduce radiation induced dermatitis in head and neck cancer patients receiving curative treatment: a pilot study. <i>Supportive Care in Cancer</i> , 2017 , 25, 1787-1795	3.9	9
117	The Case Volume Issue in Head and Neck Oncology. <i>Current Treatment Options in Oncology</i> , 2017 , 18, 65	5.4	5
116	A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2017 , 28, 2820-2826	10.3	39
115	Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?. <i>Disease Markers</i> , 2017 , 2017, 6870614	3.2	2
114	An Environment for Guideline-based Decision Support Systems for Outpatients Monitoring. <i>Methods of Information in Medicine</i> , 2017 , 56, 283-293	1.5	6
113	The vicious circle of treatment-induced toxicities in locally advanced head and neck cancer and the impact on treatment intensity. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 116, 82-88	7	6
112	A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin. <i>Annals of Oncology</i> , 2017 , 28, 2547-2551	10.3	20
111	Integrative miRNA-Gene Expression Analysis Enables Refinement of Associated Biology and Prediction of Response to Cetuximab in Head and Neck Squamous Cell Cancer. <i>Genes</i> , 2017 , 8,	4.2	21
110	Efficacy and safety of single agent pan-HER inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer (sSCC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9543-9543	2.2	5
109	Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area. <i>Oncotarget</i> , 2017 , 8, 47780-47789	3.3	22
108	RANK expression in EBV positive nasopharyngeal carcinoma metastasis: a ready-to-treat target?. <i>Oncotarget</i> , 2017 , 8, 96184-96189	3.3	4

107	Ambrosio Borsano: un exponente de la escuela de ingenier� militar de Mil� al servicio de la Monarqu� Hisp�nica (1633-1661). <i>Hispania - Revista Espanola De Historia</i> , 2017 , 77, 673	0.1	1
106	Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 97, 131-42	7	57
105	The Benefit of a Multidisciplinary Approach to the Patient Treated with (Chemo) Radiation for Head and Neck Cancer. <i>Current Treatment Options in Oncology</i> , 2016 , 17, 53	5.4	14
104	Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 959-966	4	28
103	A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. <i>European Journal of Cancer</i> , 2016 , 69, 158-165	7.5	44
102	Respiratory illness and air pollution from the steel industry: the case of Piquil�de Baixo, Brazil (Preliminary report). <i>Multidisciplinary Respiratory Medicine</i> , 2016 , 11, 41	3	4
101	Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. <i>Head and Neck</i> , 2016 , 38 Suppl 1, E2151-8	4.2	107
100	Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab. <i>Clinical Cancer Research</i> , 2016 , 22, 3961-70	12.9	53
99	Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers. <i>Head and Neck</i> , 2016 , 38, 724-31	4.2	82
98	Paranasal sinus cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 98, 45-61	7	32
97	Pain management in head and neck cancer patients undergoing chemo-radiotherapy: Clinical practical recommendations. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 99, 100-6	7	45
96	Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 102, 47-54	7	44
95	Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer?. <i>Oral Oncology</i> , 2016 , 54, 54-7	4.4	39
94	Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 100, 147-67		92
93	Sinonasal Malignancies of Anterior Skull Base: Histology-driven Treatment Strategies. <i>Otolaryngologic Clinics of North America</i> , 2016 , 49, 183-200	2	67
92	Interim results from a phase II study of CC-486 in previously treated patients (pts) with locally advanced/metastatic nasopharyngeal cancer (NPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6029-6029	2.2	0
91	Activity of afatinib administered in a window pre-operative study in squamous cell carcinoma of the head and neck (SCCHN) : EORTC-90111.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6049-6049	2.2	4
90	Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016 , 7, 74362-74379	3.3	104

89	Individual patient data meta-analysis of the IMPACT of treatment site on the outcome of head and neck cancer patients treated within 6 randomized trials.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6022-6022 ^{2,2}		
88	Safety of combination treatment with imatinib mesylate, carboplatin, and cetuximab in a patient with multiple cancers: a case report. <i>Tumori</i> , 2016 , 102,	1.7	1
87	Temporal course and predictive factors of analgesic opioid requirement for chemoradiation-induced oral mucositis in oropharyngeal cancer. <i>Head and Neck</i> , 2016 , 38 Suppl 1, E15214 ⁷²		18
86	Health care-associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy. <i>Head and Neck</i> , 2016 , 38 Suppl 1, E1009-13	4.2	5
85	Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. <i>Supportive Care in Cancer</i> , 2016 , 24, 4057-74	3.9	12
84	Absence of ALK and MET alterations in head and neck sarcomatoid carcinoma. <i>Oral Oncology</i> , 2016 , 58, e4-5	4.4	2
83	Investigational drugs for head and neck cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016 , 25, 797-811 ⁹	9.9	11
82	Searching for Evidence to Support the Use of Ginger in the Prevention of Chemotherapy-Induced Nausea and Vomiting. <i>Journal of Alternative and Complementary Medicine</i> , 2016 , 22, 486-8	2.4	7
81	Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2016 , 67, 174-182	7.5	46
80	Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. <i>Cancer Research</i> , 2015 , 75, 1205-15	10.1	63
79	Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 167-82	7	39
78	Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 372-84	7	75
77	Italian version of the M.D. Anderson Symptom Inventory--Head and Neck Module: linguistic validation. <i>Supportive Care in Cancer</i> , 2015 , 23, 3465-72	3.9	6
76	Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: Systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2015 , 51, 2596-603	7.5	44
75	Comment on Impact of intra-arterial chemotherapy including internal carotid artery for advanced paranasal sinus cancers involving the skull base? <i>British Journal of Cancer</i> , 2015 , 113, 1638-9	8.7	
74	The role of systemic therapy in the management of sinonasal cancer: A critical review. <i>Cancer Treatment Reviews</i> , 2015 , 41, 836-43	14.4	79
73	Smoothed (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. <i>Molecular Oncology</i> , 2015 , 9, 389-97	7.9	103
72	Prevention of head and neck squamous cell carcinoma: removing the "chemo" from "chemoprevention". <i>Oral Oncology</i> , 2015 , 51, 112-8	4.4	23

71	Receptor tyrosine kinase profiles and human papillomavirus status in oropharyngeal squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2015 , 44, 734-45	3.3	6
70	Nausea and vomiting during the first 3 intercycle periods in chemo-naive cancer patients receiving moderately/highly emetogenic therapy. <i>Tumori</i> , 2015 , 101, 692-6	1.7	2
69	Gastrointestinal toxicities from targeted therapies: measurement, duration and impact. <i>Current Opinion in Supportive and Palliative Care</i> , 2015 , 9, 163-7	2.6	5
68	Hope in cancer patients: the relational domain as a crucial factor. <i>Tumori</i> , 2015 , 101, 447-54	1.7	19
67	Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 95, 191-213	7	28
66	NICSO: Network Italiano Cure di Supporto in Oncologia--Italian Network for Supportive Care in Oncology. <i>Supportive Care in Cancer</i> , 2015 , 23, 11-2	3.9	4
65	Differential impact of cisplatin dose intensity on human papillomavirus (HPV)-related (+) and HPV-unrelated (HPV-) locoregionally advanced head and neck squamous cell carcinoma (LAHNSCC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6020-6020	2.2	6
64	Treatment-associated mortality in head and neck cancer receiving chemotherapy and radiation: Meta-analysis of published trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6062-6062	2.2	1
63	Health and economic outcomes of two different follow up strategies in effectively cured advanced head and neck cancer patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS6625-TPS6625	2.2	1
62	Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data. <i>Oncotarget</i> , 2015 , 6, 9627-42	3.3	79
61	Detecting characteristics of nodal invasion in advanced squamocellular oral cavity cancer through a gene expression profile on primary tumor.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e17069-e17069	2.2	
60	Upregulation of RAS pathway to predict the risk of distant metastases in HPV + oropharynx cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e17073-e17073	2.2	
59	Circulating pretreatment Epstein Barr Virus DNA quantification as a prognostic factor in nasopharyngeal cancer patients in a non endemic area.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e17054-e17054	2.2	
58	Meta-analysis: Risk of congestive heart failure (CHF) in selected targeted agents.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 64-64	2.2	
57	Prevention and treatment of oral mucositis in patients with head and neck cancer treated with (chemo) radiation: report of an Italian survey. <i>Supportive Care in Cancer</i> , 2014 , 22, 1889-96	3.9	18
56	Comprehensive gene expression meta-analysis of head and neck squamous cell carcinoma microarray data defines a robust survival predictor. <i>Annals of Oncology</i> , 2014 , 25, 1628-35	10.3	39
55	Rapid-onset opioids for the treatment of breakthrough cancer pain: two cases of drug abuse. <i>Pain Medicine</i> , 2014 , 15, 758-61	2.8	8
54	Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial. <i>Annals of Oncology</i> , 2014 , 25, 462-6	10.3	58

53	Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer. <i>Oral Oncology</i> , 2014 , 50, 884-7	4.4	14
52	Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis. <i>Annals of Oncology</i> , 2014 , 25, 694-699	10.3	27
51	Pain related to cancer treatments and diagnostic procedures: a no man's land?. <i>Annals of Oncology</i> , 2014 , 25, 1097-106	10.3	19
50	Postoperative radiotherapy with volumetric modulated arc therapy of lacrimal gland carcinoma: two case reports and literature review. <i>Future Oncology</i> , 2014 , 10, 2111-20	3.6	3
49	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. <i>Cancer</i> , 2014 , 120, 1453-61	6.4	669
48	Radiotherapy for unresectable sinonasal cancers: dosimetric comparison of intensity modulated radiation therapy with coplanar and non-coplanar volumetric modulated arc therapy. <i>Radiotherapy and Oncology</i> , 2014 , 113, 260-6	5.3	20
47	Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy. <i>Cancer Biology and Therapy</i> , 2014 , 15, 678-82	4.6	17
46	Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. <i>Supportive Care in Cancer</i> , 2013 , 21, 3191-207	3.9	107
45	Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. <i>Supportive Care in Cancer</i> , 2013 , 21, 3243-54	3.9	37
44	Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma. <i>Oral Oncology</i> , 2013 , 49, 413-9	4.4	32
43	Comments on "postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: patterns of failure" by Chan and Coll. <i>Oral Oncology</i> , 2013 , 49, e38	4.4	1
42	Critical analysis of locoregional failures following intensity-modulated radiotherapy for nasopharyngeal carcinoma. <i>Future Oncology</i> , 2013 , 9, 103-14	3.6	23
41	Emerging tyrosine kinase inhibitors for head and neck cancer. <i>Expert Opinion on Emerging Drugs</i> , 2013 , 18, 445-59	3.7	6
40	Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer. <i>Head and Neck</i> , 2013 , 35, 1471-4	4.2	13
39	Identification of a gene expression profile associated with progression-free survival (PFS) in relapsed or metastatic (RM) head and neck squamous cell cancer (HNSCC) patients (pts) treated with first-line cetuximab and platinum therapy.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 6027-6027	2.2	2
38	Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, e226-8	4.5	7
37	T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. <i>Annals of Oncology</i> , 2012 , 23, 435-41	10.3	42
36	How many therapeutic options are there for recurrent or metastatic salivary duct carcinoma?. <i>Journal of Clinical Oncology</i> , 2012 , 30, 672; author reply 672-673	2.2	4

35	Palifermin in prevention of head and neck cancer radiation-induced mucositis: not yet a definitive word on safety and efficacy profile. <i>Journal of Clinical Oncology</i> , 2012 , 30, 564-5; 565-567	2.2	16
34	Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. <i>Annals of Oncology</i> , 2012 , 23, 1832-7	10.3	82
33	Isolating p16-positive/HPV-negative oropharyngeal cancer: an effort worth making. <i>American Journal of Surgical Pathology</i> , 2011 , 35, 774-7; author reply 777-8	6.7	56
32	Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients. <i>Annals of Oncology</i> , 2011 , 22, 1886-93	10.3	19
31	Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer. <i>Annals of Oncology</i> , 2011 , 22, 2495-2500	10.3	25
30	Carcinoma del rinofaringe 2011 , 293-307		
29	Carcinomi dei seni paranasali e delle fosse nasali 2011 , 371-390		
28	TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 761-6	2.2	92
27	Multikinase inhibitors in thyroid cancer. <i>European Journal of Cancer</i> , 2010 , 46, 1012-8	7.5	13
26	Comment on "Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): a matched pair analysis", by Rades et coll. <i>Oral Oncology</i> , 2010 , 46, 888; author reply 889-90	4.4	
25	Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 179, 396-401	10.2	55
24	Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. <i>Oral Oncology</i> , 2009 , 45, 574-8	4.4	150
23	Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). <i>Oral Oncology</i> , 2009 , 45, 986-90	4.4	111
22	Further improvement in outcomes of nasopharyngeal carcinoma with optimized radiotherapy and induction plus concomitant chemotherapy: an update of the Milan experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 74, 774-80	4	33
21	Oropharyngeal squamous cell carcinoma treated with radiotherapy or radiochemotherapy: prognostic role of TP53 and HPV status. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 75, 1053-9	4	32
20	Folate in head and neck squamous cell cancer chemoprevention: purposely left out?. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3463; author reply 3463-4	2.2	2
19	Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: new options. <i>Annals of Oncology</i> , 2008 , 19 Suppl 7, vii200-3	10.3	16
18	TP53 mutations in head and neck cancer. <i>New England Journal of Medicine</i> , 2008 , 358, 1194; author reply 1195	59.2	1

17	Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. <i>Annals of Oncology</i> , 2007 , 18, 601-2	10.3	22
16	Biological agents in head and neck cancer. <i>Expert Review of Anticancer Therapy</i> , 2007 , 7, 1643-50	3.5	4
15	Biological agents in head and neck cancer. <i>Annals of Oncology</i> , 2006 , 17 Suppl 10, x45-8	10.3	3
14	High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5630-6	2.2	531
13	Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. <i>Clinical Cancer Research</i> , 2006 , 12, 6643-51	12.9	133
12	A multidisciplinary approach to squamous cell carcinomas of the head and neck: what is new?. <i>Current Opinion in Oncology</i> , 2006 , 18, 253-7	4.2	20
11	Advances in the changing patterns of aetiology of head and neck cancers. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2006 , 14, 95-9	2	7
10	Is PSA useful in the diagnosis and monitoring of parotid adenocarcinomas?. <i>Oral Oncology</i> , 2005 , 41, 219-221		
9	Herceptin plus chemotherapy in relapsed and/or metastatic salivary gland cancer. <i>Oral Oncology</i> , 2005 , 41, 97-8	4.4	17
8	Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary gland. <i>Oral Oncology</i> , 2005 , 41, 890-4.4	4.4	42
7	Is restoring platinum sensitivity the best goal for cetuximab in recurrent/metastatic nasopharyngeal cancer?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7757-8; author reply 7758-9	2.2	5
6	Cisplatin and fluorouracil concurrent to radiotherapy in nasopharyngeal cancer: is the schedule compatible?. <i>Journal of Clinical Oncology</i> , 2004 , 22, 377; author reply 377-8	2.2	1
5	Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4901-6	2.2	86
4	Head and neck tumors other than squamous cell carcinoma. <i>Current Opinion in Oncology</i> , 2004 , 16, 236-41.2	4.2	15
3	Timing of chemoradiotherapy and patient selection for locally advanced nasopharyngeal carcinoma. <i>Clinical Oncology</i> , 2003 , 15, 451-60	2.8	13
2	A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. <i>Annals of Oncology</i> , 2003 , 14, 1327-8	10.3	50
1	Confounding factors in the assessment of oral mucositis in head and neck cancer. <i>Supportive Care in Cancer</i> ,	3.9	